Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Mesothelioma, Malignant × dostarlimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Endometrial Neoplasms 7 Ovarian Neoplasms 6 Neoplasms 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 3 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Lung Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Neuroendocrine 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1 Recurrence 1 Penile Neoplasms 1 Pathologic Complete Response 1 Neoplasms, Second Primary 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1

Interventions

Cisplatin 26 Pemetrexed 21 Gemcitabine 9 Nivolumab 8 Carboplatin 8 pembrolizumab 7 tremelimumab 5 durvalumab 5 atezolizumab 5 Radiotherapy 4 Chemotherapy, Adjuvant 4 Vinorelbine 3 Ipilimumab 3 Doxorubicin 3 Bevacizumab 3 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 sodium thiosulfate 2 sargramostim 2 niraparib 2 nintedanib 2 liposomal doxorubicin 2 lenvatinib 2 defactinib 2 cemiplimab 2 amatuximab 2 Trabectedin 2 Neoadjuvant Therapy 2 Mitomycin 2 Methotrexate 2 Interferon-gamma 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03654833 2023-03-14

MiST

University of Leicester

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡